Related Experiment Videos
Intrauterine device and pelvic inflammatory disease
A G Khomassuridze1, G L Tsertsvadze, T G Tsereteli
1Zhordania Institute of Human Reproduction, Tbilisi, Republic of Georgia.
Insights
Careful patient selection and screening before IUD ML Cu375 insertion significantly reduce the risk of pelvic inflammatory disease (PID). This study monitored 620 women for 12 months, finding low PID rates.
Area of Science:
- Reproductive health
- Infectious disease prevention
- Medical device safety
Background:
- Intrauterine devices (IUDs) are effective contraceptives but carry a risk of pelvic inflammatory disease (PID).
- Bacterial contamination during IUD insertion can lead to serious reproductive health complications.
- The IUD ML Cu375 is a copper-based IUD requiring careful insertion protocols.
Purpose of the Study:
- To evaluate the safety and efficacy of the IUD ML Cu375 in preventing PID.
- To assess the impact of pre-insertion bacteriological screening on PID rates.
- To monitor the incidence of sexually transmitted diseases (STDs) in IUD users.
Main Methods:
- 620 women received the IUD ML Cu375 after undergoing bacteriological screening.
- Vaginal smears were analyzed via bacterioscopy and bacteriology at multiple time points post-insertion (7 days, 1, 3, 6, 12 months).
- Incidence of PID and STDs was recorded over the 12-month observation period.
Main Results:
- Pelvic inflammatory disease (PID) was diagnosed in 4 patients (0.6%).
- Sexually transmitted diseases (STDs) were diagnosed in 73 patients (11.8%).
- The study demonstrated a low incidence of PID in the monitored cohort.
Conclusions:
- Pre-insertion bacteriological screening is crucial for mitigating PID risk associated with IUD use.
- Careful patient selection and screening protocols can effectively reduce bacterial contamination and subsequent PID development.
- The IUD ML Cu375 can be safely used with appropriate screening measures.
Abstract:
The IUD ML Cu375 was inserted, after bacteriological screening, into 620 women who were observed for 12 months. Bacterioscopy and, when needed, bacteriology of vaginal smears were performed 7 days, and 1, 3, 6 and 12 months after insertion. During the 12 months, pelvic inflammatory disease (PID) was diagnosed in 4 patients (0.6%) and sexually transmitted disease (STD) in 73 patients (11.8%). Careful selection of patients and bacteriological screening can effectively reduce the risk of bacterial contamination and subsequent development of PID.